Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Background Accurate and rapid detection of tuberculosis (TB) and drug resistance are
critical for improving patient care and decreasing the spread of TB. Xpert® MTB/RIF assay …

Nearly 30 years after the advent of antiretroviral therapy (ART), CNS opportunistic infections
remain a major cause of morbidity and mortality in HIV-positive individuals. Unknown HIV …

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR)
tuberculosis (TB) substantially challenges TB control, especially in the European Region of …

A meta-analysis for response to treatment was undertaken using individual data of multidrug-
resistant tuberculosis (MDR-TB)(resistance to isoniazid and rifampicin) patients from 26 …

Despite the availability of effective chemotherapy, tuberculosis (TB) killed 1.3 million people
in 2012. Alongside HIV, it remains a top cause of death from an infectious disease. Global …

Extensively drug-resistant tuberculosis is a burgeoning global health crisis mainly affecting
economically active young adults, and has high mortality irrespective of HIV status. In some …

Two decades ago, WHO declared tuberculosis a global emergency, and invested in the
highly cost-effective directly observed treatment short-course programme to control the …

If tuberculosis (TB) is to be eliminated as a global health problem in the foreseeable future,
improved detection of patients, earlier diagnosis and timely identification of rifampicin …

Background Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) are World Health
Organization (WHO)‐recommended rapid tests that simultaneously detect tuberculosis and …